{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:37:39Z","timestamp":1790753859737,"version":"4.1.0"},"reference-count":107,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1080\/17474086.2016.1216311","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T15:37:46Z","timestamp":1469201866000},"page":"873-889","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders"],"prefix":"10.1080","volume":"9","author":[{"given":"Rebecca","family":"Citrin","sequence":"first","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B.","family":"Foster","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1361"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-1-9"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00120-5"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.21.12504"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402417"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.070047997"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc780"},{"issue":"11","key":"e_1_3_2_10_1","first-page":"2004","article-title":"Regulation of apoptosis proteins in cancer cells by ubiquitin","volume":"23","author":"Zhang HG","year":"2009","unstructured":"Zhang HG, Wang J, Yang X, et al. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene. 2004;23(11):2009\u20132015.","journal-title":"Oncogene"},{"key":"e_1_3_2_11_1","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-\u03baB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo JB","year":"2001","unstructured":"Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-\u03baB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419\u20131428.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1334037100"},{"issue":"4","key":"e_1_3_2_13_1","first-page":"412","article-title":"Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-\u03baB","volume":"5","author":"Wang C","year":"1999","unstructured":"Wang C, Cusack JC, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-\u03baB. Nat Am. 1999;5(4):412\u2013417.","journal-title":"Nat Am"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401705"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2301"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03102.x"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2763"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401812"},{"issue":"14","key":"e_1_3_2_19_1","first-page":"14","article-title":"Pharmacology, pharmacokinetics, and practical applications of bortezomib","volume":"18","author":"Schwartz R","year":"2004","unstructured":"Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology. 2004;18(14 Suppl 11):14\u201321.","journal-title":"Oncology"},{"key":"e_1_3_2_20_1","volume-title":"Velcade [package insert]","year":"2003","unstructured":"Velcade [package insert]. Cambridge (MA): Millenium Pharmaceuticals; 2003."},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0781"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050523"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-155"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.2878"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3170385"},{"issue":"1083","key":"e_1_3_2_27_1","article-title":"Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia","volume":"62","author":"Tan C","year":"2002","unstructured":"Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002;62:1083\u20131086.","journal-title":"Cancer Res"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.1.269"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.183"},{"key":"e_1_3_2_30_1","article-title":"Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-\u03baB inhibition","volume":"61","author":"Cusack JC","year":"2001","unstructured":"Cusack JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-\u03baB inhibition. Cancer Res. 2001;61:3535\u20133540.","journal-title":"Cancer Res"},{"key":"e_1_3_2_31_1","first-page":"1136","article-title":"The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma MH","year":"2003","unstructured":"Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136\u20131144.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0135-z"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0367-6"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1398628"},{"issue":"2","key":"e_1_3_2_35_1","first-page":"187","article-title":"The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway","volume":"67","author":"Wang H","year":"2012","unstructured":"Wang H, Wang X, Li Y, et al. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway. Pharmazie. 2012;67(2):187\u2013192.","journal-title":"Pharmazie"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1040"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01446-8"},{"key":"e_1_3_2_38_1","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc R","year":"2002","unstructured":"LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996\u20135000.","journal-title":"Cancer Res"},{"key":"e_1_3_2_39_1","first-page":"1243","article-title":"Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts","volume":"1","author":"Nawrocki ST","year":"2002","unstructured":"Nawrocki ST, Bruns CJ, Harbison MT, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2002;1:1243\u20131253.","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.106"},{"key":"e_1_3_2_42_1","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian C","year":"2002","unstructured":"Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8:2505\u20132511.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2911"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05188.x"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-508"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890410030877"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0170"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-036947"},{"issue":"9","key":"e_1_3_2_50_1","first-page":"906","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel JF","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. Leukemia. 2008;359(9):906\u2013917.","journal-title":"Leukemia"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2549"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4626"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294983"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1925-7"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6789"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0341"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0508"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4626"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.2177"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21214"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.185"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2173"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22456"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-418640"},{"key":"e_1_3_2_73_1","doi-asserted-by":"crossref","first-page":"10003","DOI":"10.1200\/jco.2013.31.15_suppl.10003","article-title":"Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: a Children\u2019s Oncology Group (COG) study (AALL07P1) [abstract]","volume":"31","author":"Horton TM","year":"2013","unstructured":"Horton TM, Lu X, O\u2019Brien MM, et al. Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: a Children\u2019s Oncology Group (COG) study (AALL07P1) [abstract]. J Clin Oncol. 2013;31:10003.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25117"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13388"},{"key":"e_1_3_2_76_1","unstructured":"Combination chemotherapy with or without bortezomib in treating younger patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02112916"},{"key":"e_1_3_2_77_1","unstructured":"Bortezomib and sorafenib tosylate in treating patients with newly diagnosed acute myeloid leukemia. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01371981"},{"key":"e_1_3_2_78_1","volume-title":"Personal communication","author":"Aplenc R","year":"2016","unstructured":"Aplenc R. Personal communication. 2016 Apr 1."},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.2174\/157489206778776925"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.005017"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601009"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535298"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2012.04.004"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318190af83"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181fdd9b0"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr465"},{"key":"e_1_3_2_87_1","unstructured":"Desensitization with bortezomib before a living kidney donation. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01842074"},{"key":"e_1_3_2_88_1","unstructured":"Bortezomib in late antibody-mediated kidney transplant rejection. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01873157"},{"key":"e_1_3_2_89_1","unstructured":"Multi-drug desensitization protocol for heart transplant candidates. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01556347"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12184"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554279"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.008"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.027"},{"key":"e_1_3_2_94_1","unstructured":"A study using tacrolimus sirolimus and bortezomib as acute graft versus host disease (GVHD) prophylaxis in allogeneic peripheral blood stem cell (PBSC) transplantation. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00670423"},{"key":"e_1_3_2_95_1","unstructured":"Bortezomib for the treatment of refractory chronic graft-vs-host disease(cGVHD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01158105"},{"key":"e_1_3_2_96_1","unstructured":"Bortezomib in patients with chronic graft versus host disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01672229"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-242917"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21950"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12815"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.06.032"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S39085"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.10.018"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2015.04.008"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_3_2_105_1","unstructured":"Study of carfilzomib in combination with dexamethasone mitoxantrone PEG-asparaginase and vincristine in children with relapsed or refractory acute lymphoblastic leukemia. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02303821"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S49187"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_2_108_1","volume-title":"Kyprolis [package insert]","year":"2012","unstructured":"Kyprolis [package insert]. Thousand Oaks (CA): Onyx Pharmaceuticals; 2012."},{"key":"e_1_3_2_109_1","volume-title":"Ninlaro [package insert]","year":"2015","unstructured":"Ninlaro [package insert]. Cambridge (MA): Millenium Pharmaceuticals; 2015."}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2016.1216311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T09:43:09Z","timestamp":1772703789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2016.1216311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1080\/17474086.2016.1216311"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2016.1216311","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}